Representative Julie Johnson (D-Texas) reported a sale of UnitedHealth Group shares on December 18th, valued between $1,001 and $15,000, in her CHASE BROKERAGE ACCOUNT (3935). The transaction was disclosed in an SEC filing on January 15th. This sale is part of a broader pattern of portfolio rebalancing by the Representative, who concurrently divested similar amounts in ten other large-cap names that same day.

In its third quarter report, UnitedHealth Group posted earnings per share of $2.92, beating consensus estimates by $0.05, and revenue of $113.16 billion, narrowly below analyst forecasts. The company achieved a 12.2% year-over-year revenue increase, a net margin of 4.04%, and a return on equity of 19.23%. It operates with a debt-to-equity ratio of 0.71 and maintains current and quick ratios of 0.82 each, underscoring solid liquidity and disciplined leverage management.

The Board declared a quarterly dividend of $2.21 per share, paid on December 16th to holders of record as of December 8th. This distribution annualizes to $8.84 per share, representing a dividend yield of approximately 2.7% based on recent trailing figures, and reflects a payout ratio of 46.14%. The consistent increase in distributions over the past five years confirms UnitedHealth Group’s commitment to shareholder returns.

Institutional ownership stands at 87.9%, with major managers such as North Capital Inc. and Sunflower Bank N.A. increasing their stakes in the third quarter. Analysts remain constructive: seventeen maintain buy ratings, nine have holds and three hold sell views, resulting in a consensus ‘Moderate Buy’. Price targets have been raised by multiple firms since October, with the average projection near $385.75, indicating expected upside from current levels driven by continued growth in both UnitedHealthcare and Optum segments.